Zanaflex (tizanidine hydrochloride)

Bes A, Eyssette M, Pierrot-Deseilligny E, Robmer F, Warter JM. A multi-centre, double-blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia. Curr Med Res Opin. 1988;10:709-718.

Coward DM. Tizanidine: neuropharmacology and mechanism of action. Neurology. 1994;44(suppl9):S6-S11.

Medici M, Pebet M, Ciblis D. A double-blind, long-term study of tizanidine (“Siralud”) in spasticity due to cerebrovascular lesions. Curr Med Res Opin. 1989;11:398-407.

Moore DP. Helping your patients with spasticity reach maximal function. Postgrad Med (serial online). 1998;104(2):107.

Nance PW, Bugaresti J, Shellenberger K., Sheremata W, Martinez-Arizala A, and the North American Tizanidine Study Group. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. Neurology. 1994;44(suppl9):S44-S52.

Nance PW, Sheremata WA, Lynch SG et al. Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis. Arch Neurol. 1997;54:731-736.

Smith C, Birnbaum G, Carter J, Greenstein J, Lublin FD, and the US Tizanidine Study Group. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. Neurology. 1994;44(suppl9): S34-S43.

Wagstaff AJ, Bryson HM. Tizanidine: a review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs. 1997;53(3):435-452.

Young RA. Spasticity: a review. Neurology. 1994;44(suppl 9):S12-S20.

Young R, Emre M, Nance PW, Shapiro RS, Barnes M. Current issues in spasticity management. Neurologist. 1997;3(4):261-275.